A 10-year retrospective study on primary and recurrent hidradenitis suppurativa

Mrinalini Alla; Patrick Kiarie; Chloe Bodden; Daphne Gonzalez Aponte; Selma Janbey; Martine A. Louis; Andrew Miele; Nageshwara Mandava

doi:10.18203/2349-2902.isj20243532

Authors

Mrinalini Alla Department of General Surgery, Flushing Hospital Medical Center, New York, USA
Patrick Kiarie Saint George University Medical School, Grenada
Chloe Bodden Department of General Surgery, Flushing Hospital Medical Center, New York, USA
Daphne Gonzalez Aponte Saint George University Medical School, Grenada
Selma Janbey Saint George University Medical School, Grenada
Martine A. Louis Department of General Surgery, Flushing Hospital Medical Center, New York, USA
Andrew Miele MediSys Health Network, Queens, New York, USA
Nageshwara Mandava mlouis2.flushing@jhmc.org

DOI:

https://doi.org/10.18203/2349-2902.isj20243532

Keywords:

HS, Recurrent disease, Primary disease, Surgical excision

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by follicular occlusion and apocrine gland inflammation. It is often misdiagnosis and delays, resulting in poor quality of life in some cases and severe consequences and poor patient outcomes. Limited literature compares presentation and treatment outcomes of recurrent HS, any information may aid clinicians in prompt diagnosis and treatment to alleviate the various challenges patients face and the complications from disease progression.

Methods: A 10-year (2012-2022) retrospective chart review of the Epic Medisys database that analyzed patients admitted to flushing hospital center with a diagnosis of HS as a primary or secondary diagnosis at our community teaching hospital in Flushing, New York.

Results: In our patient sample, HS was most commonly diagnosed in African-American and female patients under the age of 30 years. Common comorbidities included obesity. Antibiotics had the highest cure rate overall, and surgical interventions were more effective for recurrent disease.

Conclusions: From our study we concluded that most patients were African American and female presenting younger than 30 years with axillary lesions most commonly characterized as nodules and abscesses. Antibiotics had the highest cure rate for both groups; with surgical intervention more effective from recurrent disease.

Metrics

Metrics Loading ...

References

Chu CB, Yang CC, Tsai SJ. Hidradenitis suppurativa: Disease pathophysiology and sex hormones. Chin J Physiol. 2021;64(6):257-65.

Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-58.

Denny G, Anadkat MJ. The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study. J Am Acad Dermatol. 2017;76(1):54-9.

Țarcă E, Cojocaru E, Caba B, Alina CL, Solange TR, Viorel Ț, et al. Multidisciplinary management of adolescents with hidradenitis suppurativa-series of cases and literature review. J Multidiscip Healthc. 2021;14:2205-16.

Atri S, Ben Mahmoud A, Zehani A, Amine C, Wael R, Montasser JK. The management of hidradenitis suppurativa degenerating into squamous cell carcinoma: About three case reports. Ann Med Surg (Lond). 2021;64:102239.

Kim SJ, Kim TG, Gu MJ, Kim S. Mucinous adenocarcinoma of the buttock associated with hidradenitis: A case report. World J Clin Cases. 2020;8(18):4200-6.

Rekawek P, Mehta S, Andikyan V, Marco H, Konstantin Z. Squamous cell carcinoma of the vulva arising in the setting of chronic hidradenitis suppurativa: A case report. Gynecol Oncol Rep. 2016;16:28-30.

Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo J-A, Cuenca-Barrales C, Martinez-Lopez A, Arias-Santiago S, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: Systematic Review and meta-analysis. Intern J Environ Res Public Health. 2021;18(13):6709.

Sayed CJ, Hsiao JL, Okun MM. Hidradenitis Suppurativa Foundation Women's Health Subcommittee. Clinical epidemiology and management of hidradenitis suppurativa. Obstet Gynecol. 2021;137(4):731-46.

Garg A, Neuren E, Cha D, Joslyn SK, John RI, Gregor BEJ, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: Results from the global survey of impact and healthcare needs (VOICE) Project. J Am Acad Dermatol. 2020:82(2):366-76.

Micheletti RG. Hidradenitis suppurativa: Current views on epidemiology, pathogenesis, and pathophysiology. Semin Cutan Med Surg. 2014;33(3):S48-50.

Collier EK, Parvataneni RK, Lowes MA, Haley BN, Martin O, Vivian YS, et al. Diagnosis and management of hidradenitis suppurativa in women. Am J Obstet Gynecol. 2021;224(1):54-61.

Schrader AM, Deckers IE, van der Zee HH, Jurr B, Errol PP. Hidradenitis suppurativa: A retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460-7.

Wu Y, Ngaage LM, Ge S, Erin MR, Ronald PS, Yvonne MR, et al. Reconstruction for axillary hidradenitis suppurativa using one-stage local tissue rearrangement: A retrospective analysis of 53 cases. Int Wound J. 2020;17(3):701-7.

Frew JW, Navrazhina K, Marohn M. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa. Exp Dermatol. 2019;28(8):886-91.

Hotz C, Boniotto M, Guguin A, Mathieu S, Jean-Louis F, Tisserand P, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016;136(9):1768-80.

Fernandez JM, Hendricks AJ, Thompson AM, Elizabeth MM, Erin KC, Tristan RG, et al. Menses, pregnancy, delivery, and menopause in hidradenitis suppurativa: A patient survey. Int J Womens Dermatol. 2020;6(5):368-71.

Benzecry V, Grancini A, Guanziroli E, Gianluca N, Mauro B, Angelo VM, et al. Hidradenitis suppurativa/acne inversa: a prospective bacteriological study and review of the literature. G Ital Dermatol Venereol. 2020:155(4):459-63.

Ovadja ZN, Schuit MM, van der Horst CMAM, Lapid O. Inter‐and intrarater reliability of Hurley staging for hidradenitis suppurativa. Brit J Dermatol. 2019;181:344-9.

Johnston LA, Alhusayen R, Bourcier M, Isabelle D, Ralph G, Elizabeth O, et al. Practical Guidelines for Managing Patients with Hidradenitis Suppurativa: An Update. J Cutan Med Surg. 2022;26(2):2S-24.

Gulliver W, Zouboulis CC, Prens E, Gregor BEJ, Thrasivoulos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343-51.

Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization-systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19-31.

Zouboulis CC, Okun MM, Prens EP, Robert G, Peter AF, Charles L, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-9.

Yao Y, Jørgensen A-HR, Ring HC, Thomsen SF. Effectiveness of clindamycin and rifampicin combination therapy in hidradenitis suppurativa: A 6-month prospective study. Br J Dermatol. 2021;184:552-3.

Ngaage LM, Wu Y, Ge S, Gebran S, Selim G, Fan L, Erin MR, et al. Factors influencing the local cure rate of hidradenitis suppurativa following wide local excision. Int Wound J. 2020;17(1):117-23.